“Through CRISPR RNA optimization, we achieved around 59% editing at the TTR locus in our in vitro experiments. In the mouse ...
Clinical Trials Arena on MSN
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death
Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare ...
CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results